These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 30306255)
1. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255 [TBL] [Abstract][Full Text] [Related]
2. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel. Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069 [TBL] [Abstract][Full Text] [Related]
3. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Tedaldi G; Tebaldi M; Zampiga V; Danesi R; Arcangeli V; Ravegnani M; Cangini I; Pirini F; Petracci E; Rocca A; Falcini F; Amadori D; Calistri D Oncotarget; 2017 Jul; 8(29):47064-47075. PubMed ID: 28423363 [TBL] [Abstract][Full Text] [Related]
4. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844 [TBL] [Abstract][Full Text] [Related]
5. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266 [TBL] [Abstract][Full Text] [Related]
6. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population. da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725 [TBL] [Abstract][Full Text] [Related]
7. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628 [TBL] [Abstract][Full Text] [Related]
9. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110 [TBL] [Abstract][Full Text] [Related]
10. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients. Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208 [TBL] [Abstract][Full Text] [Related]
11. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
12. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance. Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693 [TBL] [Abstract][Full Text] [Related]
13. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome. Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731 [TBL] [Abstract][Full Text] [Related]
14. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077 [TBL] [Abstract][Full Text] [Related]
15. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479 [TBL] [Abstract][Full Text] [Related]
16. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313 [TBL] [Abstract][Full Text] [Related]
17. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575 [TBL] [Abstract][Full Text] [Related]
18. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center. Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613 [TBL] [Abstract][Full Text] [Related]
20. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]